利妥昔单抗联合改良CHOP方案治疗非霍奇金淋巴瘤的临床疗效及安全性评价  

Rituximab combined with CHOP chemotherapy regimen in the treatment of relapsing non-hodgkin's lymphoma

作　　者：张燕萍[1] 周晓慧[1] 张丽[1] 马光丽[2] 

机构地区：[1]江山市中医院血液内科,浙江江山324100 [2]温州医科大学附属第六医院血液科,浙江丽水323000

出　　处：《中国临床药理学杂志》2015年第12期1109-1111,共3页The Chinese Journal of Clinical Pharmacology

基　　金：中医药行业科研专项基金资助项目(201107001-14)

摘　　要：目的：评价利妥昔单抗联合改良CHOP方案（600 mg· m－2环磷酰胺，第1天＋1．4 mg· m－2长春新碱，第1天＋泼尼松60 mg，第1～5天＋25 mg· m－2阿霉素，第1天）治疗复发难治性非霍奇金淋巴瘤的临床疗效及安全性。方法将62例复发难治性非霍奇金淋巴瘤患者随机分为试验组29例和对照组33例。对照组：改良 CHOP 方案联合10 mg· m－2博来霉素，第1天＋75 mg· m－2足叶乙苷，第1～5天；试验组：在改良CHOP方案实施前2 d，静脉输注375 mg· m－2利妥昔单抗。2组1个周期均为21 d，共治疗4～6个周期。分析比较2组患者的临床疗效及不良反应发生率。结果试验组的客观缓解率93．10％显著高于对照组75．76％（P＜0．05）。试验组平均缓解时间（14．6±3．8）个月显著长于对照组（6．4±2．2）个月（P＜0．05）。2组患者不良反应发生率比较差异无统计学意义（P＞0．05）。结论利妥昔单抗联合改良CHOP方案治疗复发难治性非霍奇金淋巴瘤临床的疗效确切，可显著延长患者的疾病缓解时间。Objective To assess the effects and safety of rituximab com-bined with CHOP chemotherapy regimen （ 600 mg· m-2 cytoxan on day 1＋1.4 mg· m-2 vinblastine on day 1＋prednisone 60 mg on day 1 to 5＋25 mg· m-2 adriamycin on day 1 ） in the treatment of relapsing non-hodgkin′s lymphoma.Methods A total of 62 cases of relapsing non-hodgkin′s lymphoma were divided into experiment group （ n=29 ） and control group （ n =33 ） .Patients in the control group were given CHOP regimen combined with 10 mg· m-2 bleomycin on day 1 and 5 mg· m-2 etoposide on day 1 to 3.Patients in experiment group were given 375 mg· m-2 rituximab 2 days before CHOP chemotherapy.All of the patients underwent 4 to 6 cycles of chemotherapy （21 days was a cy-cle）.The clinical effects and adverse reactions were evaluated between the two groups.Results The objective response rate were 93.10%and 75.76%in experiment and control group respectively （ P 〈0.05 ） .The mean complete response time were （ 14.6 ±3.8 ） months in experiment group, higher than（6.4 ±2.2） months in control group（ P〈0.05）.The main adverse reaction in two groups were not statistically different （P〉0.05）.Conclusion Rituximab combined with CHOP chemothera-py regimen can improve the clinical efficacy and complete response time on patients with relapsing non-hodgkin′s lymphoma.

关 键 词：利妥昔单抗 改良CHOP方案 非霍奇金淋巴瘤 临床疗效 

分 类 号：R979.1[医药卫生—药品] R733[医药卫生—药学]